This vaccination season could be a key moment for vaccine makers and investors. That's because it's offering us a first glimpse into the future coronavirus vaccine revenue opportunity. Companies have predicted the market may follow that of the flu shot, which suggests 50% of the U.S. population may go for an annual jab. The idea is people will opt for a coronavirus vaccine once a year, and that would equal recurrent revenue for vaccine companies.

In the pandemic's earlier days, (NYSE: PFE) and Moderna dominated as Novavax (NASDAQ: NVAX) fell behind, entering the market much later. This fall, though, these companies all launched updated vaccines around the same time -- so the idea is Novavax has a fair chance of carving out market share. But, could a recent comment by Pfizer indicate trouble for this vaccine underdog? Let's find out.

First, it's important to say all three companies have produced vaccines backed by positive scientific data. They've also built out the infrastructure necessary to manufacture and deliver these vaccines. The main question moving forward is whether people will indeed go for coronavirus vaccines as readily as they go for flu shots every year.

Continue reading

Source Fool.com